DelveInsight’s “PD-L1 Inhibitors Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of PD-L1 inhibitors epidemiology, market, and clinical development, along with historical and forecasted market data and PD-L1 inhibitors market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the PD-L1 Inhibitors Market with DelveInsight’s In-Depth Report @ PD-L1 Inhibitors Market Size
Key Takeaways from the PD-L1 Inhibitors Market Report
The leading PD-L1 inhibitors companies include Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis, and others.
The overall PD-L1 inhibitors market across the 7MM was valued at nearly USD 36 billion in 2023, with the United States generating the largest share of that total, at approximately USD 26 billion.
Testing of PD-L1 inhibitors in clinical trials has roughly tripled in recent years, with over 4,400 trials recorded and more than 3,600 still ongoing; combination approaches accounted for around 90% of trials initiated in 2020, underscoring a decisive shift toward combination strategies.
KEYTRUDA remains the dominant PD-L1 inhibitor in the US market, while OPDIVO holds the leading position in Japan after reclaiming market share it briefly lost to KEYTRUDA. LIBTAYO leads in non-melanoma skin cancers such as cutaneous squamous cell carcinoma and basal cell carcinoma, and TECENTRIQ leads in small-cell lung cancer.
Patent expirations for KEYTRUDA and OPDIVO’s intravenous formulations are set for 2028 in the US, a milestone expected to reshape the competitive landscape and open the door to biosimilar entrants, though emerging players targeting narrower indications are likely to face difficulty fully displacing the two incumbents.
Stay ahead in the PD-L1 Inhibitors Market with DelveInsight’s Strategic Report @ PD-L1 Inhibitors Market Outlook
PD-L1 Inhibitors Epidemiology Segmentation in the 7MM
Incident Cases of Select Indications for PD-(L)1 Inhibitors in the US, 2024
NSCLC: approximately 200,000 incident cases
Melanoma: approximately 100,700 incident cases
Cutaneous Squamous Cell Carcinoma: approximately 1,207,400 incident cases
Triple-Negative Breast Cancer (TNBC): approximately 44,400 incident cases
Urothelial Carcinoma: approximately 86,300 incident cases
PD-L1 Inhibitors Pipeline Analysis
KEYTRUDA (pembrolizumab): Merck
KEYTRUDA is a monoclonal antibody that blocks PD-1, first approved by the FDA in September 2014 for advanced melanoma and since expanded to cover roughly 20 indications, including a January 2024 approval for FIGO 2014 Stage III–IVA cervical cancer. In May 2025, Phase III data from the ASCENT-04/KEYNOTE-D19 study were presented as a late-breaking oral presentation at ASCO 2025. A supplemental application for resectable locally advanced head and neck squamous cell carcinoma was accepted for priority review by the FDA in February 2025, with a target action date of June 23, 2025.
IMFINZI (durvalumab): AstraZeneca
IMFINZI is a human monoclonal antibody targeting PD-(L)1, first approved by the FDA in February 2018 for Stage III NSCLC and now covering four indications: NSCLC, extensive-stage small-cell lung cancer, biliary tract cancer, and hepatocellular carcinoma. In June 2025, IMFINZI combined with FLOT chemotherapy showed a statistically significant improvement in event-free survival versus chemotherapy alone in resectable gastric and gastroesophageal junction cancers. Worldwide sales reached roughly USD 4 billion in 2023, driven primarily by the NSCLC indication.
Sasanlimab: Pfizer
Sasanlimab is a humanized IgG4 monoclonal antibody targeting PD-1, currently being evaluated in the pivotal Phase III CREST trial in combination with BCG for BCG-naïve, high-risk non-muscle invasive bladder cancer. Positive topline results were announced in January 2025, with further results reported in April 2025.
HLX43: Shanghai Henlius Biotech
HLX43 is an antibody-drug conjugate targeting PD-L1 and is the most advanced asset of its kind progressing into Phase II development globally, having received IND approvals from both China’s NMPA and the US FDA. It is being studied across multiple solid tumor types, including NSCLC, thymic squamous cell carcinoma, hepatocellular carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, cervical cancer, and nasopharyngeal cancer. In June 2025, the first patient was dosed in HLX43-NSCLC201, a Phase II international trial developed with MediLink Therapeutics; earlier Phase I data presented at ASCO 2025 showed a manageable safety profile and encouraging efficacy across NSCLC subtypes regardless of EGFR mutation status, metastasis, or PD-L1 expression.
PD-L1 Inhibitors Market Insights
Checkpoint inhibitors targeting PD-L1 have become central to modern immuno-oncology, with ten PD-(L)1 inhibitors approved in the United States — seven targeting PD-1 and three targeting PD-L1. KEYTRUDA’s breadth of approved indications has made it the clear market leader, though rising concern over adverse events is pushing developers toward combination regimens that pair PD-L1 blockade with agents targeting CTLA-4, TIGIT, LAG-3, and novel targets such as TROP-2.
A major formulation advance came in September 2024, when Roche received FDA approval for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first subcutaneous PD-L1 inhibitor, cutting administration time from 30–60 minutes to roughly seven minutes across all adult indications approved for intravenous TECENTRIQ.
Beyond PD-1/PD-L1 itself, newer targets such as TIGIT and TIM-3 have faced high-profile setbacks after early promise, while LAG-3 and MHC Class II agonist approaches remain active areas of combination-focused development. Bristol Myers Squibb has also developed a subcutaneous formulation of OPDIVO, with US patent protection for that formulation extending to 2030, as part of a broader effort to offset the impact of upcoming biosimilar competition.
Get In-Depth Knowledge on PD-L1 Inhibitors Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/pd-L1-inhibitors-market
PD-L1 Inhibitors Market Outlook
PD-1 and PD-L1 inhibitors work by blocking the interaction between the PD-1 receptor on T cells and the PD-L1 protein expressed on tumor cells, an interaction cancer cells otherwise exploit to evade immune attack. Since the first approvals of KEYTRUDA and OPDIVO in 2014, the drug class has expanded from late-stage metastatic disease into early-stage settings such as triple-negative breast cancer and non-small-cell lung cancer, and now includes seven PD-1-directed therapies (KEYTRUDA, OPDIVO, LIBTAYO, JEMPERLI, ZYNYZ, LOQTORZI, and TEVIMBRA) alongside three PD-L1-directed therapies (TECENTRIQ, BAVENCIO, and IMFINZI).
PD-1 inhibitors are expected to continue outselling PD-L1 inhibitors through the forecast period, largely on the strength of KEYTRUDA’s broad label. Still, the approaching 2028 patent cliff for KEYTRUDA and OPDIVO is expected to reshape competitive dynamics considerably, even as newer entrants such as ZYNYZ — approved for Merkel cell carcinoma and projected to reach close to USD 50 million in US sales by 2034 — work to carve out share in a crowded field. Differentiation through first-in-class approvals, underserved indications, and combination strategies is expected to be the key lever for companies competing against the two market leaders.
Scope of the PD-L1 Inhibitors Market Report
Coverage: 7MM (US, EU4, UK, Japan)
Study Period: 2020–2034
Forecast Period: 2024–2034
PD-L1 Inhibitors Companies: Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis, and others
PD-L1 Inhibitors Therapies: KEYTRUDA, OPDIVO, LIBTAYO, TECENTRIQ, BAVENCIO, IMFINZI, and others
PD-L1 Inhibitors Market Access & Reimbursement, Unmet Needs and Perspectives
PD-L1 Inhibitors SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive PD-L1 Inhibitors Market Report @ PD-L1 Inhibitors Market Drivers and Barriers
Table of Contents
Key Insights
Report Introduction
Executive Summary of PD-(L)1 Inhibitors
Key Events
Epidemiology and Market Forecast Methodology
PD-(L)1 Inhibitors Market Overview at a Glance in the 7MM
PD-(L)1 Inhibitors Background and Overview
Epidemiology and Patient Population
Marketed Drugs
Emerging Drugs
PD-(L)1 Inhibitors: The 7MM Analysis
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Related Reports
PD-1 and PD-L1 Inhibitors- Competitive Landscape, 2026
DelveInsight’s, “PD-1 and PD-L1 Inhibitors – Competitive landscape, 2026,” report provides comprehensive insights about 180+ companies and 200+ drugs in PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/pd-L1-inhibitors-market
